Alnylam和Roche开始对Zilebesiran进行重大试验,这是对高血压的新疗法。 Alnylam and Roche begin a major trial for zilebesiran, a new treatment for high blood pressure.

Alnylam制药公司和Roche公司正在启动第三阶段试验,以测试新的RNAi疗法Zilebesiran,降低高血压失控患者的主要心脏病风险。 Alnylam Pharmaceuticals and Roche are starting a Phase 3 trial to test zilebesiran, a new RNAi therapeutic, for lowering major heart risks in patients with uncontrolled high blood pressure. 根据第二阶段的结果,Zilebesiran降低了血压,如果试验成功,可以提供重大的健康惠益。 Based on Phase 2 results, zilebesiran reduced blood pressure and could offer significant health benefits if the trial is successful. 这场名为ZENITH的审判将涉及约11 000名病人。 The trial, called ZENITH, will involve around 11,000 patients.